Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02003222
Title Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute lymphoblastic leukemia

Therapies

Cytarabine

Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate

Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate

Cyclophosphamide + Cytarabine + Mercaptopurine + Pegaspargase

Methotrexate + Pegaspargase

Cytarabine + Etoposide + Methotrexate

Rituximab

Blinatumomab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.